Adolescence is a critical period of development, often accompanied by serious mental health challenges. Conditions such as depression, anxiety, eating disorders, and mood disorders have become increasingly common among young people. Depression, in particular, has seen a dramatic rise, with a 2022 report from Mental Health America showing that 10.6% of adolescents are now affected by severe major depression. The COVID-19 pandemic has further intensified this mental health crisis, doubling rates of depression and anxiety and driving a concerning increase in suicides among children and adolescents. Many young people are struggling to find relief, as traditional treatments like antidepressants and talk therapy fail to meet their needs. The surge in mental health issues has also coincided with rising rates of suicide and school shootings, while mental health resources remain limited and stretched thin. In light of this escalating crisis, the need for innovative and effective treatment options has never been more urgent—especially for those who don’t respond well to standard therapies. One promising alternative is Ketamine-Assisted Psychotherapy (KAP), which offers new hope for more effective mental health interventions.
Clinical guidelines for managing adolescent depression in the acute phase recommend a combination of selective serotonin reuptake inhibitors (SSRIs), psychotherapy, or both, with cognitive behavioral therapy (CBT) being the most extensively studied approach. SSRIs are the most commonly prescribed antidepressants for adolescents, with the FDA approving fluoxetine for children aged 8 and older and escitalopram for those aged 12 and older.
Despite the effectiveness of these treatments, approximately 40% of adolescents fail to achieve an adequate response, a condition known as treatment-resistant depression (TRD). TRD is linked to a higher likelihood of depression recurrence, as well as an increased risk of anxiety disorders and suicide. Additionally, untreated depression in adolescence can have lasting consequences, as those with major depressive disorder are more likely to experience ongoing depression and develop other mental health disorders in adulthood.
Initially developed as an anesthetic, ketamine has gained recognition in recent years for its ability to rapidly reduce symptoms of depression, anxiety, and suicidality, especially in treatment-resistant cases. Unlike traditional antidepressants, which can take weeks to show effects, ketamine can provide rapid relief, often within hours or days. This rapid action is particularly important in adolescents, where untreated depression and other mental health conditions can lead to severe consequences, including suicide.
Ketamine works by blocking NMDA receptors in the brain, which enhances activity in the glutamate system, a key pathway involved in neuroplasticity. This process stimulates the production of Brain-Derived Neurotrophic Factor (BDNF), which plays a critical role in promoting the growth and strengthening of neural connections. As a result, ketamine not only elevates mood but also helps foster new, healthier patterns of thought and behavior, making it effective for both emotional regulation and long-term mental health improvement.
While ketamine has shown promise as a stand-alone treatment, its integration into a psychotherapeutic context amplifies its therapeutic potential. Ketamine-Assisted Psychotherapy (KAP) involves administering ketamine in a controlled setting, accompanied by therapy sessions that help patients process and integrate the experiences they have while under the influence of the drug.
For adolescents, KAP offers a unique opportunity to explore their inner worlds in a safe and supported environment. The dissociative effects of ketamine create a “time-out” from the intense emotions and negative thought patterns that often dominate the minds of those with mental health struggles. This mental space allows for introspection and emotional exploration, often resulting in breakthroughs that might take months or even years to achieve through traditional therapy alone.
One of the key components of successful adolescent treatment is family involvement. Adolescents are deeply embedded in their family systems, and unresolved family conflicts or stressors can contribute to or exacerbate mental health issues. In KAP, involving family members in the therapeutic process is critical. Parents can support their child’s journey and help create a home environment that promotes healing and growth.
Family therapy, combined with ketamine sessions, has shown to help reduce conflict, enhance understanding, and support adolescents in developing autonomy and self-worth.
The potential benefits of KAP for adolescents are substantial. It can help reduce depression, alleviate suicidal ideation, and improve emotional regulation. Moreover, ketamine’s ability to induce rapid changes in mood makes it particularly useful for adolescents who are at immediate risk of harm. However, KAP is not a one-size-fits-all solution. Careful screening and preparation are essential to determine if an adolescent is a good candidate for the therapy.
This study aimed to assess the safety and efficacy of intravenous ketamine in adolescents with major depressive disorder (MDD). Seventeen adolescents (ages 13-17) received a single infusion of ketamine (0.5 mg/kg), with depression severity measured 24 hours post-infusion.
The results demonstrated a significant reduction in depressive symptoms, with 76% of participants responding within the first 3 days. The antidepressant effects appeared to persist for up to 14 days. Importantly, no serious adverse events were reported, suggesting that ketamine is both well-tolerated and effective in reducing depressive symptoms in adolescents. It’s worth noting that these findings are based on a single infusion, while standard treatment protocols typically involve a series of six infusions, which may lead to more sustained effects over time.
Safety is always a concern when using powerful medications like ketamine, but the evidence thus far supports its safety and tolerability in adolescents when administered in controlled, clinical environments. Side effects, such as nausea are usually mild and short-lived, and most adolescents cope well with the altered states induced by ketamine.
When administered in a controlled clinical setting under the supervision of a medical professional, ketamine is not considered habit-forming or addictive. However, the same cannot be said for its use outside of this environment. When adolescents use ketamine at home or in recreational settings without proper oversight, the risk of misuse and dependence significantly increases. To explore more about ketamine’s safety profile, potential side effects, and concerns around abuse, be sure to read: Ketamine: Navigating Risks, Mitigating Misuse, and Confronting Potential Addiction.
While ketamine can be an effective option for treating depression in adolescents, it should not necessarily be considered a first-line treatment. It is often advisable to start by consulting with a psychiatrist, who may recommend beginning with traditional antidepressant therapy, either on its own or in combination with ketamine therapy. The adolescent brain is still in a critical phase of development and neuroplasticity, which can lead to varied responses to ketamine treatment.
Although we have observed significant relief in many cases, it’s important to recognize that some adolescents may experience treatment resistance. Managing expectations and having open, transparent discussions with the adolescent’s healthcare team is crucial to ensure the best outcome. Collaborative care that includes child psychiatrists, therapists, and parents is essential for tailoring a treatment plan that meets the unique needs of each adolescent.
In conclusion, Ketamine-Assisted Psychotherapy (KAP) represents a promising approach for adolescents with complex psychiatric conditions. When integrated with therapeutic support, its ability to rapidly reduce symptoms of depression and anxiety makes it a valuable tool in addressing the current adolescent mental health crisis. As research and clinical experience continue to unfold, KAP may become a widely accepted and vital part of adolescent mental health care.
About the Author
Dr. Ray Rivas, a former general and trauma surgeon with over a decade of experience utilizing ketamine, became a ketamine therapy specialist to treat mental health and pain after witnessing its profound impact on his hospital trauma patients and his own mental health. As the founder and medical director of Innerbloom Ketamine Therapy in San Luis Obispo, California, Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Disclaimer: All content on this website, including (but not limited to) this statement, news, blog post, article, testimonial, or FAQ is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can do that. Therefore, we cannot be responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to the Terms & Conditions for more information.